Bicycle Therapeutics Limited (NASDAQ:BCYC) has been given a consensus recommendation of “Buy” by the eight analysts that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have given a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $24.80.
A number of analysts recently issued reports on BCYC shares. HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of Bicycle Therapeutics in a research note on Thursday, August 6th. Zacks Investment Research lowered Bicycle Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday. BidaskClub upgraded Bicycle Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday. Canaccord Genuity upped their target price on Bicycle Therapeutics from $23.50 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Finally, Oppenheimer restated a “buy” rating and issued a $27.00 target price on shares of Bicycle Therapeutics in a research note on Tuesday, September 22nd.
Hedge funds have recently modified their holdings of the stock. FMR LLC purchased a new stake in Bicycle Therapeutics during the 2nd quarter valued at about $3,277,000. Morgan Stanley lifted its holdings in Bicycle Therapeutics by 32,450.0% in the 1st quarter. Morgan Stanley now owns 3,255 shares of the company’s stock worth $44,000 after buying an additional 3,245 shares during the period. Squarepoint Ops LLC purchased a new stake in Bicycle Therapeutics in the 1st quarter worth approximately $179,000. UBS Group AG purchased a new stake in Bicycle Therapeutics in the 2nd quarter worth approximately $36,000. Finally, Advisor Group Holdings Inc. lifted its holdings in Bicycle Therapeutics by 34,000.0% in the 2nd quarter. Advisor Group Holdings Inc. now owns 34,100 shares of the company’s stock worth $537,000 after buying an additional 34,000 shares during the period. Institutional investors own 35.54% of the company’s stock.
NASDAQ:BCYC opened at $18.51 on Thursday. Bicycle Therapeutics has a 52-week low of $7.50 and a 52-week high of $21.59. The firm has a market cap of $327.63 million, a price-to-earnings ratio of -8.90 and a beta of -0.42. The business’s fifty day moving average is $18.98 and its 200 day moving average is $16.92.
Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.19). Bicycle Therapeutics had a negative net margin of 434.29% and a negative return on equity of 43.74%. The company had revenue of $1.57 million for the quarter, compared to the consensus estimate of $2.11 million. On average, sell-side analysts predict that Bicycle Therapeutics will post -2.49 EPS for the current fiscal year.
Bicycle Therapeutics Company Profile
Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.
Recommended Story: How to use beta for portfolio diversification
Receive News & Ratings for Bicycle Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bicycle Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.
